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Alpha-fetoprotein (AFP) is an oncofetal protein found in high 
concentrations in fetal and maternal blood and in patients with 
certain neoplastic and non-neoplastic disorders [1]. AFP was 
fIrst identified in 1956, in 2 separate laboratories during electro-
phoretic e~peri~ents on plasma prote.ins of neonates,. as a 
protein which migrated between albunun and exI-globuhn [2]. 
Clinical interest in AFP developed when it was discovered that 
transplantable hepatocellular carcinoma of the mouse synthe-
sized and secreted AFP into the blood [3]. High serum levels of 
AFP were subsequently detected in patients with hepatoma, 
germ cell tumors and certai~ ~ther neoplastic an~ non-neoplas-
tic disorders [1,4,5]. In additIOn to mammals, bU'ds and even 
several species of shal'ks have been found to synthesize a fetal-
specific plasma alpha-globulin analogous to mammalian AFP 
[5]. The main site of AFP synthesis has shifted during evolution 
from fetal stomach in sharks to yolk sac in birds to liver in 
mammals, all derived from the same endodermal origin [5]. 
These ancient evolutionary ancestors of human AFP suggest a 
necessary function of AFP in developmental biology that still 
remains poorly defined . 
Interest in AFP currently exists in areas such as develop-
mental biology, immunoregulation, oncology and prenatal di-
agnosis of certain congenital anomalies. This briefreview covers 
. some of the current knowledge about AFP and is intended to 
kindle interest in the subject among dermatologists and other 
investigators in the field of cutaneous biology. 
STRUCTURAL AND BIOCHEMICAL 
PROPERTIES OF AFP 
AFP is a single-chain sialylated glycoprotein composed of 
approximately 580 amino acid residues and 3-4% carbohydrate 
[1]. The molecular weight of AFP has been estimated to be 
about 67,000 Daltons by SDS gel electrophoresis. AFP is a 
negatively charged protein with an isoelectric point of pH 4.57 
to 5.08. These variations in charge, due only in part to sialic 
acid content, do not affect the antigenic properties of this 
protein. Several (at least 3) species of AFP have been isolated 
by extended agarose gel electrophoresis and crossed immuno-
electrophoresis. There is a correlation between the relative 
amounts of the most negatively charged species and the inhib-
itory effect of AFP on in vitro transformation of lymphocytes 
[1]. Treatment with neuraminidase to remove completely the 
sialic acid residues does not alter the biologic potency. Thus 
differences in sialic acid content are only partly responsible for 
the microheterogeneity of AFP and variability of other charged 
regions is also present [6]. In addition to the monomeric forms, 
polymers including dimeric and trim eric forms have been iden-
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tified which dissociate into the monomer upon exposure to 
disulfide reducing agents, implying that their formation is de-
pendent upon intermolecular sulfide bonds. 
The chemical and antigenic structures of AFP's isolated from 
various mammals are closely related. In addition, no antigenic 
differences have been identified between AFP's isolated from 
tumor bearing adults and from fetal sources [1,4]. Immunization 
of an animal with its own AFP does not lead to antibody 
formation because of tolerance. Tolerance can be broken by 
altering AFP or by immunization with a cross-reacting AFP 
from another species. These antibodies can then eliminate the 
animal's normal serum AFP [4]. 
Another interesting and not yet fully explored property of 
AFP is the high affinity of murine AFP for certain estrogens by 
means of which APP could influence cell growth. Human AFP 
has a much lower estrogen binding ability [7]. 
BIOSYNTHESIS AND SERUM LEVELS OF AFP 
Synthesis of AFP by the human embryo can be detected as 
early as 29 days after conception [1]. As the yolk sac becomes 
atretic by 11 to 12 weeks of gestation, AFP synthesis occurs 
predominantly in fetal hepatocytes although a small amount 
may be produced by the fetal gut. AFP levels in fetal serum 
reach a maximum of 3,000 J.Lg perml at about 14th week of 
gestation, exceeding in its concentration all other fetal plasma 
proteins including albumin. Serum concentrations decrease 
thereafter to 200 to 300 J.Lg per ml at age 32 weeks of gestation, 
to 20 to 120 J.Lg per ml at term and then drop sharply after birth. 
During the first 2 mo of life serum levels are about 400 ng per 
ml, fall to 30 ng per ml by 6 mo of age and to less than 15 ng per 
ml by 1 to 2 yr. Thereafter, serum AFP levels are maintained 
between 3 and 15 ng per ml due to synthesis of AFP which has 
a biological half life of about 6 days. During adult life serum 
levels can rise again in the event of occurrence of regenerative 
or neoplastic proliferation of hepatocytes and of a number of 
extrahepatic tumors [1]. 
The dynamics of AFP and albumin synthesis have been 
studied by a number of investigators [8,9]. The serum levels 
seem to correlate with the number of hepatocytes which pro-
duce this protein. In experiments with rat hepatoma lines, it 
has been shown that some clones produce high levels of AFP 
and low levels of albumin and others the reverse. Moreover 
albumin and AFP are produced during different phases of cell 
cycle. AFP is synthesized during Gland S phase while albumin 
is produced from mid-S through G2 [4,10]. Immunofluorescence 
studies have shown that AFP and albumin are probably syn-
thesized in different hepatic cells. The synthesis of AFP in t he 
developing liver is regulated at the level of m-RNA. The level 
of AFP mRNA in adult liver is greatly reduced [11]. The 
synthesis of serum AFP was studied in 16 human embryos and 
fetuses between 4.2 and 18 weeks of gestation by incubation of 
selected tissues with 14C-labeled amino acids followed by im-
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munoelectrophoresis of the culture fluids and radioautography. 
Relatively large amounts of radioactive AFP were found in 
each of the liver cultures and in cultures of the developing yolk 
sac. Smaller amounts of labeled AFP were observed in almost 
all of the gastrointestinal tract cultures. Labeled AFP was 
formed in the kidney cultures from 1 of 9 conceptuses and in 
only 1 of 14 placentas cultured. None of the cultures of lung, 
thymus, pancreas, skeletal muscle, amnion or chorion produced 
detectable amounts of AFP. 
The immunological techniques for the quantitation of AFP 
vary greatly in their sensitivity. High levels of AFP can be 
measured by single radial immunodiffusion or rocket immuno-
electrophoresis. Smaller amounts (5 to 500 ng per ml) are 
commonly quantitated by radioimmunoassay [1]. 
PHYSIOLOGICAL PROPERTIES OF AFP 
The exact physiological function of AFP remains unknown 
[1,4]. Some consider it to be a form offetal albumin. Speculation 
exists that AFP may be involved in immunoregulation during 
pregnancy. The supportive evidence is mostly based on in vitro 
experiments. Laboratory studies have demonstrated that mu-
rine AFP exerts an immunosuppressive effect on antibody 
synthesis [12]. AFP has been shown to induce the formation of 
highly efficient suppressor T cells with capacity to inhibit 
helper T cells, but with no effect on B cells responding to 
thymus independent antigens [1,4]. AFP has been shown to 
suppress the mitogenic response of human lymphocytes to 
phytomitogens, antihuman thymocyte antiserum and mixed 
lymphocyte culture. In order to achieve maximum inhibition 
AFP must be present at the time of mitogen addition [13]. Pre-
exposure of lymphocytes to AFP followed by washing does not 
result in lymphocyte suppression. Increased concentrations of 
mitogen cannot overcome the inhibitory effects of AFP. This 
implies that AFP does not act by simple competition with the 
lymphocyte membrane for the mitogen combining site. Also 
the lymphocyte response to phytomitogens or anti-human thy-
mocyte antiserum cannot be totally suppressed by increasing 
doses of AFP, suggesting the presence of a subpopulation of T 
lymphocytes [13]. Murine AFP has been reported to bind to a 
subpopulation of T lymphocytes [14]. We have not been able 
to detect similar high binding affinity of human AFP to human 
lymphocytes. 
On the basis of these findings it has been suggested that AFP 
helps maintain the fetus as an allograft in a genetically incom-
patible environment. Administration of anti-AFP antisera to 
pregnant mice and rabbits has been abortogenic [15]. Although 
the mechanism of the induced abortion is unknown it is con-
ceivable that neutralization of AFP at the maternal/fetal inter-
face might initiate rejection ofthe fetus through a cell-mediated 
immune reaction [15]. 
CLINICAL SIGNIFICANCE OF AFP 
Liver Disorders 
Approximately 10 to 20% of patients with nonmalignant liver 
diseases including infectious hepatitis and cirrhosis have ele-
vated serum AFP levels ranging from 25 to 500 ng per ml. In 
serial determinations these levels tend to be fluctuant and 
transient. On the other hand steady or rising serum AFP levels 
particularly exceeding 500 ng per ml are indicative of primary 
liver cell cancer. In screening a group of cirrhotics, who have a 
higher than normal risk for developing hepatoma, 22% had 
elevated serum AFP levels. Of these, about 10% were ultimately 
diagnosed as having hepatoma [1,3-5]. 
The incidence of elevated serum AFP levels in hepatoma 
ranges from 50 to 90% depending on the geographical location. 
Certain pathologic features are correlated with the appearance 
of AFP in liver cancer. Size of the tumor is related to the 
number of samples positive for AFP but not to the level of 
AFP. AFP is synthesized more frequently and in higher 
amounts by faster growing tumors and more undifferentiated 
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cancer cell lines. Also younger patients with hepatoma are more 
frequently AFP-positive than elderly ones. Only a small pro-
portion of tumor cells make AFP. Less than 5 to 20% of cells 
have been found by immunofluorescence to be positive for AFP. 
Exposure to even small amounts of hepatocarcinogenic sub-
stances such as 3'-methyl-4-dimethylaminoazobenzene and N-
2-fluorenylacetamide can cause a rapid and significant elevation 
of serum AFP levels in rats [16]. In patients with hepatoma, if 
there is no therapeutic intervention, the serum AFP usually 
increases gradually as the tumor progresses. Complete surgical 
resection of the tumor produces an immediate exponential fall 
that parallels the catabolic decay rate for AFP. Recurrence of 
elevated AFP levels will almost certainly mean tumor recur-
rence [1]. 
Other Tumors and Diseases 
Elevated serum AFP levels have been associated with germ 
cell tumors containing elements of yolk sac or endodermal' sinus 
components [1]. In mixed germ cell tumors and in pure tumors 
of extraembryonic origin derived from yolk sac AFP elevations 
are present. Pure seminomas of the testis or dysgerminomas of 
the ovary are not associated with serum AFP elevations. Ele-
vated serum AFP levels have been reported in association with 
various carcinomas of the gastrointestinal tract particularly 
gastric and pancreatic cancers, in retinoblastoma and in some 
nonmalignant conditions such as cystic fibrosis, Turner's syn-
drome, heriditary tyrosinemia and ataxia telangiectasia 
[1,4,17]. 
Skin Tumors 
Elevated serum AFP levels have been reported in a few cases 
of malignant melanoma and in a patient with basal cell carci-
noma [17,18]. AFP was also detected in tissue of a case of 
Bowen's disease by immunofluorescence techniques [19]. A 
systematic study of serum and tissue samples in large numbers 
of patients with various cutaneous disorders would be needed 
to assess the significance of AFP in dermatology. 
AFP in Pregnancy 
Elevation of AFP levels in maternal blood and in amniotic 
fluid has been found helpful in the detection of multiple preg-
nancy, congenital nephrosis, intrauterine fetal death, hydro-
cephalus, hemolytic disease secondary to Rh isoimmunization, 
omphalocele, duodenal or esophageal atresia, threatened or 
missed abortion, placental separation and open neural tube 
defects such as anencephaly, meningocele and myelocele 
[1,4,5]. 
SUMMARY 
Detection and measurement of serum AFP levels have been 
found useful in the diagnosis, prognosis and follow up of patients 
with hepatoma and germ cell tumors [20]. Monitoring maternal 
and amniotic fluid AFP concentration helps detect a variety of 
fetal disorders. The in vitro evidence for immunosuppressive 
effects of AFP suggests a possible role of AFP in immunoregu-
lation. 
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Announcement 
Pacific Dermatologic Association Essay Contest 
The 31st Annual Meeting of the Pacific Dennatologic Association will be held in San F rancisco, 
California, September 16-20, 1979. E ach yeal" the Pacific Derma tologic Association encourages young 
dermatologists to submit essays on original work. The Nelson Paul Anderson Memorial E ssay Contest is 
open to all physicians in graduate dermatologic training or those who are not more than· 5 years ou t of 
residency training. Essays may be submitted by residents of the geogr aphical area of the Pacific 
Dermatologic Association: The Western United States (California, Oregon, Alaska, Nevada, Washington, 
Idaho, Utah , Arizona, H awaii, Montana, Wyoming, Colorado, New Mexico), British Columbia and 
Alberta, Canada, Mexico, Australia, N ew Zealand, J apan, and the Philippines. The winning essayist will 
receive a cash prize of $500 plus expenses to t he next Annual Meeting. His/ her sponsoring department 
will receive $250 for educational materials. 
Essays will be judged on the following considerations: A. Originality; B. Potential importance of work; 
C. Evaluation of results; D . Experimental methods and use of control; and E . Clarity of presentation. Six 
copies of the essay should be submitted under a nom-de-plume, with no info rmation in the paper which 
will lead to recognition by the judges of the instit ut ion or clinic where the work was done. The essay with 
nom-de-plume should be accompanied by a plain sealed envelope enclosing the name and address and 
nom-de-plume of the author. Entries must be received by the Secretary-Treasurer, Gerald A. Gellin, 
M .D ., 3838 California St., San Francisco, California 94118, no later t han July 15, 1979. 
